Drug Trial Radar · NCT07494435
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Jun 1, 2028
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Zhejiang Haichang Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer or advanced kidney cancer.
Conditions
- Hepato Cellular Carcinoma (HCC)
- Renal Cell Cancer
Interventions
WGI-0301Drug
WGI-0301 at Maximum Tolerated Dose (MTD)
Nivolumab (240 mg)Drug
Nivolumab is given as an intravenous infusion, every 2 weeks
WGI-0301Drug
WGI-0301 at dose level below Maximum Tolerated Dose (MTD-1)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of WGI-0301 in Combination with NivolumabTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China Pharmaceutical University, Shanghai Gobroad Cancer Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.